| scholarly article | Q13442814 |
| P2093 | author name string | Soon-Sun Hong | |
| Mi-Hyun Kim | |||
| Juyoung Kim | |||
| Kyung Hee Jung | |||
| Soo Jung Kim | |||
| Hong Hua Yan | |||
| Mi Kwon Son | |||
| Zhenghuan Fang | |||
| Ye-Lim Ryu | |||
| P2860 | cites work | Cancer statistics, 2014 | Q27861018 |
| Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications | Q28506804 | ||
| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer | Q29547638 | ||
| Pancreatic cancer | Q29616288 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis | Q33588267 | ||
| Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer | Q33868282 | ||
| Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas | Q34037769 | ||
| Developing c-MET pathway inhibitors for cancer therapy: progress and challenges | Q34089725 | ||
| An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms | Q34625881 | ||
| Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma | Q35004346 | ||
| Does more accurate exposure prediction necessarily improve health effect estimates? | Q35370777 | ||
| Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond | Q35596686 | ||
| The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer | Q36907124 | ||
| The anaplastic lymphoma kinase in the pathogenesis of cancer | Q37039605 | ||
| Inhibition of ALK signaling for cancer therapy | Q37593792 | ||
| Anaplastic Lymphoma Kinase: Role in specific tumours, and development of small molecule inhibitors for cancer therapy | Q37799137 | ||
| Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases | Q37820500 | ||
| Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment | Q37862882 | ||
| c-MET as a potential therapeutic target and biomarker in cancer | Q37962905 | ||
| Anaplastic lymphoma kinase as a therapeutic target. | Q38045455 | ||
| Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition | Q38064218 | ||
| New molecular targets in the treatment of NSCLC. | Q38080101 | ||
| Anti-cancer effect of HS-345, a new tropomyosin-related kinase A inhibitor, on human pancreatic cancer | Q39166185 | ||
| HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis | Q39289182 | ||
| Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification | Q39325851 | ||
| c-Met in pancreatic cancer stem cells: therapeutic implications. | Q42426376 | ||
| MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations | Q42731321 | ||
| SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities | Q43559869 | ||
| Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. | Q43800126 | ||
| Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer | Q45106840 | ||
| Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer | Q46602989 | ||
| Expression and Prognostic Significance of CD151, c-Met, and Integrin alpha3/alpha6 in Pancreatic Ductal Adenocarcinoma | Q54645357 | ||
| Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer | Q72571222 | ||
| c-Met is a marker of pancreatic cancer stem cells and therapeutic target | Q84816959 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreatic cancer | Q212961 |
| crizotinib | Q5186964 | ||
| P304 | page(s) | 9150-9168 | |
| P577 | publication date | 2014-10-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer | |
| P478 | volume | 5 |
| Q52902964 | Clinical Advanced in Early-stage ALK-positive Non-small Cell Lung Cancer Patients |
| Q92133931 | Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer |
| Q36020888 | Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling |
| Q58574781 | HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers |
| Q36759077 | Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment |
| Q26787087 | Novel agents for advanced pancreatic cancer |
| Q37624480 | Pancreatic stellate cell: Pandora's box for pancreatic disease biology |
| Q90620375 | Promising new treatments for pancreatic cancer in the era of targeted and immune therapies |
| Q28081193 | Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets |
Search more.